Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Welcome and Introduction to Vi3C

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Jan
17
Today In Oncology
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
HCC LLM Advice and Treatment Concordance
Can a Genetic Variant Affect the Efficacy of Abiraterone
Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo